Mascoma Wealth Management LLC Has $64,000 Stock Position in Abbott Laboratories (NYSE:ABT)

Mascoma Wealth Management LLC grew its holdings in Abbott Laboratories (NYSE:ABT) by 23.6% during the 4th quarter, Holdings Channel reports. The firm owned 570 shares of the healthcare product maker’s stock after purchasing an additional 109 shares during the period. Mascoma Wealth Management LLC’s holdings in Abbott Laboratories were worth $64,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Impax Asset Management Group plc grew its holdings in Abbott Laboratories by 0.5% during the 3rd quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock worth $63,573,000 after acquiring an additional 2,754 shares during the period. United Bank boosted its position in shares of Abbott Laboratories by 1.8% in the 3rd quarter. United Bank now owns 27,284 shares of the healthcare product maker’s stock worth $3,111,000 after purchasing an additional 488 shares during the last quarter. Versor Investments LP acquired a new stake in shares of Abbott Laboratories during the third quarter worth $651,000. Verus Capital Partners LLC lifted its stake in Abbott Laboratories by 7.5% in the third quarter. Verus Capital Partners LLC now owns 5,705 shares of the healthcare product maker’s stock valued at $650,000 after buying an additional 400 shares during the period. Finally, Dillon & Associates Inc. boosted its holdings in Abbott Laboratories by 2.1% during the third quarter. Dillon & Associates Inc. now owns 210,347 shares of the healthcare product maker’s stock worth $23,980,000 after buying an additional 4,364 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Bank of America increased their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a research report on Monday. Evercore ISI increased their target price on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Argus raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. The Goldman Sachs Group raised their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company boosted their target price on Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $137.94.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,449 shares of company stock worth $15,463,316. Insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Down 1.8 %

Shares of ABT stock opened at $130.29 on Thursday. The firm’s fifty day moving average price is $126.57 and its two-hundred day moving average price is $119.21. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The firm has a market capitalization of $225.97 billion, a P/E ratio of 17.03, a PEG ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.2% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.81%. Abbott Laboratories’s dividend payout ratio is presently 30.85%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.